12
Participants
Start Date
March 11, 2022
Primary Completion Date
August 20, 2027
Study Completion Date
December 30, 2027
LYG-LIV0001
Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
RECRUITING
Houston Methodist Hospital, Houston
WITHDRAWN
Tufts Medical Center, Boston
Lead Sponsor
LyGenesis, Inc.
INDUSTRY